英国与荷兰老年可手术乳腺癌患者治疗与生存差异——两项国家前瞻性纵向多中心队列研究的比较
比较英国Age Gap队列3262例与荷兰Climb队列618例≥70岁可手术乳腺癌患者,两组均行基线老年综合评估。英国原发内分泌治疗(16.6% vs 7.3%)和术后辅助内分泌治疗(62.2% vs 38.8%)均约为荷兰两倍,但调整后总生存无显著差异(HR 0.94,95%CI 0.74-1.17,P=0.568)。
要点
- 英国原发内分泌治疗16.6% vs 荷兰7.3%,术后辅助内分泌治疗62.2% vs 38.8%,均P<0.001。
- 调整后总生存无显著差异(HR 0.94,95%CI 0.74-1.17,P=0.568)。
- 中位随访:Age Gap 4.1年(IQR 2.9-5.4),Climb 4.3年(IQR 2.9-5.5)。
核心结论
- 与既往研究不同,该两项大型国家前瞻性纵向多中心队列比较显示,尽管治疗分配存在差异,英国与荷兰老年乳腺癌患者总生存相当。
研究设计与样本
- 比较英国Age Gap队列3262例与荷兰Climb队列618例≥70岁可手术乳腺癌患者的两项国家前瞻性纵向多中心队列研究。
- 两队列均行基线老年综合评估,收集年龄、合并症、认知、营养与功能状态、基线肿瘤特征及治疗类型。
- 采用单变量和多变量Cox回归模型比较队列间总生存。
主要发现
- Age Gap中位年龄77.0岁(IQR 72.0-81.0),Climb中位年龄75.0岁(IQR 72.0-81.0)。
- 两队列总体可比,合并症与衰弱率略有差异。
- Age Gap原发内分泌治疗率为16.6%,Climb为7.3%(P<0.001);Age Gap术后辅助内分泌治疗率为62.2%,Climb为38.8%(P<0.001)。
- 总生存无显著差异:调整后HR 0.94(95%CI 0.74-1.17,P=0.568)。
关键数值与推荐
- 原发内分泌治疗:Age Gap 16.6% vs Climb 7.3%(P<0.001)。
- 术后辅助内分泌治疗:Age Gap 62.2% vs Climb 38.8%(P<0.001)。
- 总生存调整后HR 0.94(95%CI 0.74-1.17,P=0.568),无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have shown that survival outcomes for older patients with breast cancer vary substantially across Europe, with worse survival reported in the United Kingdom. It has been hypothesised that these differences in survival outcomes could be related to treatment variation. OBJECTIVES: We aimed to compare patient and tumour characteristics, treatment selection and survival outcomes between two large prospective cohorts of older patients with operable breast cancer from the United Kingdom (UK) and The Netherlands. METHODS: Women diagnosed with operable breast cancer aged ≥70 years were included. A baseline comprehensive geriatric assessment was performed in both cohorts, with data collected on age, comorbidities, cognition, nutritional and functional status. Baseline tumour characteristics and treatment type were collected. Univariable and multivariable Cox regression models were used to compare overall survival between the cohorts. RESULTS: 3262 patients from the UK Age Gap cohort and 618 patients from the Dutch Climb cohort were included, with median ages of 77.0 (IQR: 72.0-81.0) and 75.0 (IQR: 72.0-81.0) years, respectively. The cohorts were generally comparable, with slight differences in rates of comorbidity and frailty. Median follow-up for overall survival was 4.1 years (IQR 2.9-5.4) in Age Gap and 4.3 years (IQR 2.9-5.5) in Climb. In Age Gap, both the rates of primary endocrine therapy and adjuvant hormonal therapy after surgery were approximately twice those in Climb (16.6% versus 7.3%, p < 0.001 for primary endocrine therapy, and 62.2% versus 38.8%, p < 0.001 for adjuvant hormonal therapy). There was no evidence of a difference in overall survival between the cohorts (adjusted HR 0.94, 95% CI 0.74-1.17, p = 0.568). CONCLUSIONS: In contrast to previous studies, this comparison of two large national prospective longitudinal multi-centre cohort studies demonstrated comparable survival outcomes between older patients with breast cancer treated in the UK and The Netherlands, despite differences in treatment allocation.
引用
- van der Plas-Krijgsman WG, Morgan JL, de Glas NA, et al. Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies. Eur J Cancer. 2022. PMID: 35081505. doi:10.1016/j.ejca.2021.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。